Jazz Pharmaceuticals plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| J7Z.F | LGND | KRYS | XENE | 688177.SS | ZLAB | |
|---|---|---|---|---|---|---|
| Market cap | 12.28B | 6.23B | 9.52B | 3.49B | 7.37B | 2.71B |
| P/E (TTM) | 15.1 | 32.9 | 40.3 | — | — | — |
| Forward P/E | 10.7 | 26.1 | 35.9 | -7.6 | -26.2 | -11.5 |
| Price/book | 2.9 | 6.4 | 7.0 | 2.8 | 59.5 | 4.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +59.09% | +65.11% | +74.56% | −14.01% | −33.37% | −13.78% |
| Today | −0.24% | +1.97% | −1.19% | −0.68% | −0.56% | −3.65% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All J7Z.F news ›Jazz Pharmaceuticals PLC $JAZZ Position Lifted by CWA Asset Management Group LLC
Posted by Defense World Staff on Oct 20th, 2026 Get Our Latest Research Report on Jazz Pharmaceuticals Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its…
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it will report its 2026 third quarter financial results on Monday, November 2, 2026,... DUBLIN, Oct. 19, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)…
Jazz Pharmaceuticals: 9-Month CXO Transformation | Veeva Systems Europe
Pay clinical research sites faster Streamline and automate training Provide investigator and site data Collect and verify site data Aggregate and clean study data Plan and manage submissions Publish to health authorities Manage all quality…
Jazz Pharmaceuticals: Ziihera And Portfolio Diversification Are Changing The Earnings Story
Seeking Alpha - Jazz Pharmaceuticals is transforming beyond oxybate reliance, with diversified growth across sleep medicine, epilepsy, and oncology portfolios. - JAZZ delivered robust Q2 2026 results: $1.21B revenue (+16% YoY), strong…
Return From an Inspiring Few Days at the EANO2026 and the Reflections – Jazz Pharmaceuticals
Jazz Pharmaceuticals shared on LinkedIn: “As we return from an inspiring few days at the European Association of Neuro-Oncology 2026 meeting, our team is reflecting on the critical insights and shared commitment that will shape the future…
Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'
Corteva: "There is absolutely no reason you would want to own this one over Vylor." Onto Innovation: "We're going to take a harder look at Onto because it's another one of these companies that's process control solutions, and they're all…
Jazz Pharmaceuticals Drops 5.1% Amid Sector-Wide Selling
AlphaStreet AlphaStreet Newsdesk powered by AlphaStreet Intelligence Jazz Pharmaceuticals plunged 5.1% on Thursday as a sector-wide selloff dragged down biotechnology stocks. The company’s shares fell to $219.46 on volume of 241,863 shares…
Jazz Pharmaceuticals director proposes $3.36M sale
A director proposes selling Jazz Pharmaceuticals (JAZZ) shares after a $436K sale. Stock Titan Jazz Pharmaceuticals director proposes $3.36M sale Morgan Stanley Smith Barney LLC is listed as broker, and the proposed-sale shares are…
Jazz Pharmaceuticals Falls as Traders Weigh Minor Target Cut and Recent Insider-Sale Filings
Jazz Pharmaceuticals (JAZZ) is down 4.5% today. Here is some analysis on what might have caused this price movement. Analysis: The catalyst is not completely clear, but the drop appears tied to a softer analyst price-target revision and…
Jazz Pharmaceuticals CEO sells 2,000 shares
Direct holdings stood at 141,394 shares after CEO Renee D. Gala's October 6, 2026 sale under a trading plan adopted June 4, 2026, without discretion. - [Form 4] Jazz Pharmaceuticals plc Insider Trading Activity Jazz Pharmaceuticals CEO…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net4
-
cnbc.com1
-
defenseworld.net1
-
gurufocus.com1
-
news.alphastreet.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.